TY - JOUR
T1 - Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems
AU - Dijk, Frederike
AU - Veenstra, Veronique L.
AU - Soer, Eline C.
AU - Dings, Mark P.G.
AU - Zhao, Lan
AU - Halfwerk, Johannes B.
AU - Hooijer, Gerrit K.
AU - Damhofer, Helene
AU - Marzano, Marco
AU - Steins, Anne
AU - Waasdorp, Cynthia
AU - Busch, Olivier R.
AU - Besselink, Marc G.
AU - Tol, Johanna A.
AU - Welling, Lieke
AU - van Rijssen, Lennart B.
AU - Klompmaker, Sjors
AU - Wilmink, Hanneke W.
AU - van Laarhoven, Hanneke W.
AU - Medema, Jan Paul
AU - Vermeulen, Louis
AU - van Hooff, Sander R.
AU - Koster, Jan
AU - Verheij, Joanne
AU - van de Vijver, Marc J.
AU - Wang, Xin
AU - Bijlsma, Maarten F.
N1 - Funding Information: The authors would like to sincerely thank the patients for participating in the study. Furthermore, they thank Drs Roel Kluin and Iris de Rink from the Netherlands Cancer Institute for technical support. This work was supported by a KWF Dutch Cancer Society grant to M.J.V., O.R.B., and H.L. UVA 2014-6803 and to M.F.B. and H.L. UVA 2012-5607, UVA 2013-5932, as well as grants from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. CityU 11102317, 11103718), a grant supported by the Young Scientists Fund of the National Natural Science Foundation of China (81802384) awarded to X.W. None were involved in the study design or drafting of the manuscript. We thank Life Science Editors for editorial assistance. Funding Information: The authors declare no competing interests. H.L. has acted as a consultant for BMS, Eli Lilly and Company, and Nordic Pharma Group, and has received unrestricted research grants from Bayer Schering Pharma AG, BMS, Celgene, Eli Lilly and Company, Nordic Pharma Group, Philips, and Roche Pharmaceuticals. M.F.B. has received research funding from Celgene, and has acted as a consultant for Servier. None of these were involved in drafting of the manuscript. Publisher Copyright: © 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all common cancers. However, divergent outcomes exist between patients, suggesting distinct underlying tumor biology. Here, we delineated this heterogeneity, compared interconnectivity between classification systems, and experimentally addressed the tumor biology that drives poor outcome. RNA-sequencing of 90 resected specimens and unsupervised classification revealed four subgroups associated with distinct outcomes. The worst-prognosis subtype was characterized by mesenchymal gene signatures. Comparative (network) analysis showed high interconnectivity with previously identified classification schemes and high robustness of the mesenchymal subtype. From species-specific transcript analysis of matching patient-derived xenografts we constructed dedicated classifiers for experimental models. Detailed assessments of tumor growth in subtyped experimental models revealed that a highly invasive growth pattern of mesenchymal subtype tumor cells is responsible for its poor outcome. Concluding, by developing a classification system tailored to experimental models, we have uncovered subtype-specific biology that should be further explored to improve treatment of a group of PDAC patients that currently has little therapeutic benefit from surgical treatment.
AB - Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all common cancers. However, divergent outcomes exist between patients, suggesting distinct underlying tumor biology. Here, we delineated this heterogeneity, compared interconnectivity between classification systems, and experimentally addressed the tumor biology that drives poor outcome. RNA-sequencing of 90 resected specimens and unsupervised classification revealed four subgroups associated with distinct outcomes. The worst-prognosis subtype was characterized by mesenchymal gene signatures. Comparative (network) analysis showed high interconnectivity with previously identified classification schemes and high robustness of the mesenchymal subtype. From species-specific transcript analysis of matching patient-derived xenografts we constructed dedicated classifiers for experimental models. Detailed assessments of tumor growth in subtyped experimental models revealed that a highly invasive growth pattern of mesenchymal subtype tumor cells is responsible for its poor outcome. Concluding, by developing a classification system tailored to experimental models, we have uncovered subtype-specific biology that should be further explored to improve treatment of a group of PDAC patients that currently has little therapeutic benefit from surgical treatment.
UR - http://www.scopus.com/inward/record.url?scp=85077941505&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41598-019-56826-9
DO - https://doi.org/10.1038/s41598-019-56826-9
M3 - Article
C2 - 31941932
SN - 2045-2322
VL - 10
SP - 337
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 337
ER -